Alpha helix mimetics and methods relating thereto
| Title: | Alpha helix mimetics and methods relating thereto |
|---|---|
| Patent Number: | 9,040,531 |
| Publication Date: | May 26, 2015 |
| Appl. No: | 13/319071 |
| Application Filed: | May 07, 2010 |
| Abstract: | Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. |
| Inventors: | Odagami, Takenao (Yokohama, JP); Kogami, Yuji (Yokohama, JP); Kouji, Hiroyuki (Yokohama, JP) |
| Assignees: | PRISM BioLab Co., Ltd. (Yokohama-shi, JP) |
| Claim: | 1. A compound having the following general formula (I): [chemical expression included] wherein is single bond or double bond; A is —CHR 7 —, wherein R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3; G and Y are independently carbon atom or nitrogen atom; R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—or —(SO 2)—, W 22 is bond, —O—, —NH— or optionally substituted lower alkylene, Rb is bond or optionally substituted alkylene, and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; with the proviso that when B is benzene, and R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl; or a pharmaceutically acceptable salt thereof. |
| Claim: | 2. The compound of claim 1 , wherein R 3 is hydrogen or optionally substituted alkyl. |
| Claim: | 3. The compound of claim 1 , which has the following general formula (I-d): [chemical expression included] wherein is single bond or double bond; A is —(CHR)—; wherein R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3; G is carbon atom or nitrogen atom; R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—or —(SO 2)—, W 22 is bond, —O—, —NH— or optionally substituted lower alkylene, Rb is bond or optionally substituted lower alkylene, and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; with the proviso that when B is benzene, and R 2 is —W 21 —W 22 —Rb 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl. |
| Claim: | 4. The compound of claim 1 , wherein B is optionally substituted 5-membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y. |
| Claim: | 5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. |
| Claim: | 6. A compound having the following general formula (II): [chemical expression included] wherein is single bond or double bond; A is —CHR 7 —, wherein R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3; G and Y are independently carbon atom or nitrogen atom; R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—or —(SO 2)—, W 22 is bond, —O—, —NH—or optionally substituted lower alkylene, Rb is bond or optionally substituted alkylene, and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R 91 is selected from optionally substituted alkyl, linker and solid support; and R 92 is selected from optionally substituted alkyl, linker and solid support; with the proviso that when B is benzene, and R 21 is W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl; or a salt thereof. |
| Claim: | 7. A process for preparing a compound having the following general formula (I): [chemical expression included] wherein is single bond or double bond; A is —CHR 7 —, wherein R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3; G and Y are independently carbon atom or nitrogen atom; R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl; R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—or —(SO 2)—, W 22 is bond, —O—, —NH— or optionally substituted lower alkylene, Rb is bond or optionally substituted alkylene, and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; with the proviso that when B is benzene, and R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl; or a salt thereof, which comprises reacting a compound having the following general formula (II): [chemical expression included] wherein R 91 is selected from optionally substituted alkyl, linker and solid support; R 92 is selected from optionally substituted alkyl, linker and solid support; and the other symbols are as defined above, or a salt thereof, with an acid. |
| Current U.S. Class: | 514/243 |
| Patent References Cited: | 5440013 August 1995 Kahn 5929237 July 1999 Kahn 6013458 January 2000 Kahn 6762185 July 2004 Kahn 7067507 June 2006 Pulley et al. 7232822 June 2007 Moon et al. 2005/0004131 January 2005 Flohr 2005/0209256 September 2005 Andres 2005/0222158 October 2005 Andres WO 94/03494 February 1994 WO 01/00210 January 2001 WO 01/16135 March 2001 WO 03/031448 April 2003 WO 2004/035587 April 2004 WO 2004/072077 August 2004 WO 2004/093828 November 2004 WO 2005/021025 March 2005 WO 2005/116032 December 2005 WO 2006/101858 September 2006 WO 2007/056513 May 2007 WO 2007/0056593 May 2007 WO 2007/056593 May 2007 WO 2009/051397 April 2009 WO 2009/0148192 December 2009 WO 2009/148192 December 2009 WO 2010/0044485 April 2010 WO 2010/044485 April 2010 |
| Other References: | Chemical Abstract Service (CAS) Registry Database. American Chemical Society (ACS). cited by examiner National Cancer Institute. “Cancer Prevention Overview.” © Apr. 2014, Available from: < http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page3/print >. cited by examiner “List of Cancer Chemotherapy Drugs.” (2013), Available from: https://www.navigatingcancer.com/library/all/chemotherapy—drugs >. cited by examiner Cystic Fibrosis Foundation. “Treatments.” © 2014. Available from: < http://www.cff.org/treatments/ >. cited by examiner Drugs.com “Cystic Fibrosis.” (c) 2014. Available from: < http://www.drugs.com/health-guide/cystic-fibrosis.html?printable=1 >. cited by examiner Mayo Clinic. “Pulmonary fibrosis.” © 2014. Available from: < http://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/basics/definition/con-20029091?p=1 >. cited by examiner Mayo Clinic. “Cystic Fibrosis.” © 2015. Available from: < http://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/basics/causes/con-20013731?p=1 >. cited by examiner Pulmonary Fibrosis Foundation. “Treatment Options.” © 2015. Available from: < http://www.pulmonaryfibrosis.org/life-with-pf/pulmonary-fibrosis-treatment-options >. cited by examiner Dangas, G., et al. “Restenosis: Repeat Narrowing of a Coronary Artery.” Circulation. (2002), vol. 105, pp. 2586-2587. cited by examiner Mayo Clinic. “Polycystic kidney disease.” (c) 2015. Available from: < http://www.mayoclinic.org/diseases-conditions/polycystic-kidney-disease/basics/definition/con-20028831?p=1 >. cited by examiner Kay, N., et al. “The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia.” Semin. Oncol. (2006), vol. 33, pp. 174-185. cited by examiner Mayo Clinic. “Tuberous sclerosis.” © 2015. Available from: < http://www.mayoclinic.org/diseases-conditions/tuberous-sclerosis/basics/treatment/con-20032953 >. cited by examiner Chang-Moore Cancer Virology Laboratory. “Kaposi's Sarcoma-Associated Herpesvirus (KSHV).” © 2015. Available from: < http://www.tumorvirology.pitt.edu/kshvrsch.html >. cited by examiner Mayo Clinic. “Hair Loss.” © 2015. Available from: < http://www.mayoclinic.org/diseases-conditions/hair-loss/basics/definition/con-20027666?p=1 >. cited by examiner Mayo Clinic. “Alzheimer's disease.” © 2015. Available from: < http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/care-at-mayo-clinic/why-choose-mayo-clinic/con-20023871?p=1 >. cited by examiner Chemical Abstract Service (CAS) Registry Database. © 1998. American Chemical Society (ACS). cited by examiner Adnot, 2005, The Journal of Clinical Investigation, 115(6): 1461-1463. cited by applicant Albranches et al., 2003, Biotechnology Letters, 25: 725-730. cited by applicant Bao et al., 2000, Gynecologic Oncology, 78: 373-9. cited by applicant Behrens et al., 1996, Nature, 382: 638-642. cited by applicant Bellusci et al., 1997, Development, 124: 4867-4878. cited by applicant Bienz et al., 2000, Cell, 103: 311-20. cited by applicant Bitar et al., 1999, Cell and Tissue Research, 298: 233-242. cited by applicant Blanc-Brude et al., 2002, Nature Medicine, 8: 987-994. cited by applicant Borok et al., 1995, American Journal of Respiratory Cell and Molecular Biology, 12: 50-55. cited by applicant Bouvet et al., 2002, Cancer Research, 62: 1534-1540. cited by applicant Brown et al., 2000, Digestive Diseases and Sciences, 45: 1578-84. cited by applicant Caca et al., 1999, Cell Growth & Differentiation, 10: 369-376. cited by applicant Cadigan et al., 1997, Genes & Development, 11: 3286-3305. cited by applicant Cao et al., 1999, Clinical Cancer Research, 5: 267-274. cited by applicant Carri et al., 1994, International Journal of Developmental Neuroscience, 12: 567-578. cited by applicant Chauvet et al., 1996, Glia, 18: 211-223. cited by applicant Chen et al., 2001, The Journal of Cell Biology, 152: 87-96. cited by applicant Chilosi et al., 2003, American Journal of Pathology, 162: 1495-1502. cited by applicant Cho et al., 1999, Plant Molecular Biology, 40: 419-429. cited by applicant Chrivia et al., 1993, Nature, 365: 855-859. cited by applicant Chu et al., 2003, Neuroscience Letters, 343: 129-133. cited by applicant Clark et al., 2001, American Journal of Physiology—Lung Cellular and Molecular, 280: L705-L715. cited by applicant Collingwood et al., 1999, Journal of Molecular Endocrinology, 23: 255-275. cited by applicant Crawford et al., 1999, Oncogene, 18: 2883-2891. cited by applicant Crispino, et al., 1999, Molecular Cell, 3: 219-228. cited by applicant Daniels et al., 2001, Trends in Biochemical Sciences, 26: 672-678. cited by applicant Danto et al., 1995, American Journal of Respiratory Cell and Molecular Biology, 12: 497-502. cited by applicant DasGupta et al., 1999, Development 126: 4557-4568. cited by applicant Davis et al., 2002, Cancer Research, 62: 7247-7253. cited by applicant Demidem et al., 2001, Cancer Research, 61: 2294-2300. cited by applicant Deng et al., 2003, Experimental Neurology, 182: 373-382. cited by applicant Dinsmore, 1999, Journal of the American Osteopathic Association, 99(9) Suppl.: 1S. cited by applicant Dinsmore, 1999, Journal of the American Osteopathic Association, 99(9) Suppl.: 6S. cited by applicant Eckner et al., 1994, Genes & Development, 8: 869-884. cited by applicant Eguchi et al., “Solid-Phase Synthesis and Structural Analysis of Bicyclic β-Turn Mimetics Incorporating Functionality at the i to i + 3 Positions,” Journal of the American Chemical Society, 1999, pp. 12204-12205, vol. 121. cited by applicant Eguchi et al., “Solid-phase synthesis and solution structure of bicyclic β-turn peptidomimetics: diversity at the i position,” Tetrahedron Letters, 2001, pp. 1237-1239, vol. 42. cited by applicant Eguchi et al., “Design, Synthesis, and Evaluation of Opioid Analogues with Non-Peptidic β-Turn Scaffold: Enkephalin and Endomorphin Mimetics,” Journal of Medicinal Chemistry, 2002, pp. 1395-1398, vol. 45. cited by applicant Fleisher et al., 1996, Advanced Drug Delivery Reviews, 19: 115-130. cited by applicant Fox et al., 1999, Revue Neurologique (Paris), 155 Suppl. 4: S33-7. cited by applicant Fraser et al., 2001, Biochemical Society Symposia, 67: 89-100. cited by applicant Fuchs, 1999, The Harvey Lectures, 94: 47-78. cited by applicant Fujimuro et al., 2003, Nature Medicine, 9: 300-306. cited by applicant Fukunaga et al., 1999, Cell Transplantation, 8: 435-441. cited by applicant Gallop et al., 1994, Journal of Medicinal Chemistry, 37: 1233-1251. cited by applicant Gat et al., 1998, Cell, 95: 605-614. cited by applicant Goff et al., 1991, Genes & Development, 5: 298-309. cited by applicant Gomez, 1995, Brain and Development, vol. 17, Supplement 1, 55-57. cited by applicant Gong et al., 1999, Plant Molecular Biology, 41: 33-44. cited by applicant Graminski et al., 1994, Biotechnology, 12: 1008-1011. cited by applicant Grube et al., 2004, Herz, 29: 162-166. cited by applicant Guo et al., 2002, Cancer Research, 62: 4678-4684. cited by applicant Gurwitz, 2000, Trends in Neurosciences, 23: 386. cited by applicant Hanai et al., 2002, The Journal of Cell Biology, 158: 529-539. cited by applicant Hayashi et al., 1997, Proceedings of the National Academy of Sciences of USA, 94: 242-247. cited by applicant He et al., 1998, Science, 281: 1509-1512. cited by applicant He et al., 1999, Cell, 99: 335-345. cited by applicant Hecht et al., 2000, EMBO Journal, 19: 1839-1850. cited by applicant Hirata et al., 1997, Journal of Neurobiology, 32: 415-25. cited by applicant Hobo et al., 1999, Proceedings of the National Academy of Sciences of USA, 96: 15348-15353. cited by applicant Hollenberg et al., 1995, Molecular and Cellular Biology, 15: 3813-3822. cited by applicant Hsu et al., 1998, Molecular and Cellular Biology, 18: 4807-4818. cited by applicant Hunter, 2006, Advanced Drug Delivery Reviews, 58: 347-349. cited by applicant Janknecht et al., 1996, Nature, 383: 22-23. cited by applicant Jue et al., 1992, Molecular and Cellular Biology, 12: 321-328. cited by applicant Kapanci et al., 1995, American Journal of Respiratory and Critical Care Medicine, 152: 2163-2169. cited by applicant Kasper et al., 1996, Histology and Histopathology, 11: 463-483. cited by applicant Kato et al., 1983, Developmental Brain Research, 11: 143-147. cited by applicant Kawamorita et al., 2002, Human Cell, 15: 178-182. cited by applicant Kawanami et al., 1982, Laboratory Investigation, 46: 39-53. cited by applicant Khalil et al., 1991, American Journal of Respiratory Cell and Molecular Biology, 5: 155-162. cited by applicant Kinzler et al., 1996, Cell, 87: 159-170. cited by applicant Kispert et al., 1996, Development, 122: 3627-3637. cited by applicant Kolligs et al., 1999, Molecular and Cellular Biology, 19: 5696-5706. cited by applicant Koo et al., 1993, Proceedings of the National Academy of Sciences of USA, 90: 4748-4752. cited by applicant Koutsourakis et al., 2001, Mechanisms of Development, 105: 105-114. cited by applicant Kril et al., 2001, International Review of Neurobiology, 48: 167-217. cited by applicant Kudo et al., 2003, Biochemical Pharmacology, 66: 289-295. cited by applicant Kurz et al., 2002, Journal of neural transmission. Supplementum, 62: 127-33. cited by applicant Labonte et al., 2000, Hepatology Research, 18: 72-85. cited by applicant Lacza et al., 2003, Brain Research Protocols, 11: 145-154. cited by applicant Lam et al., 1991 Nature 354: 82-84. cited by applicant Landesman-Bollag et al., 2001, Oncogene, 20: 3247-3257. cited by applicant Lemere et al., 2003, Neurochemical Research, 28: 1017-1027. cited by applicant Lemon et al., 1999, Current Opinion in Genetics & Development, 9: 499-504. cited by applicant Leo et al., 2000, Gene, 245: 1-11. cited by applicant Li et al., 2000, Developmental Biology, 248: 68-81. cited by applicant Lin et al., 2001, Developmental Dynamics, 222: 26-39. cited by applicant Litingtung et al., 1998, Nature Genetics, 20: 58-61. cited by applicant Lu et al., 1999, Breast Cancer Research and Treatment, 57: 183-92. cited by applicant Mak, et al., 2003, The Journal of Biological Chemistry, 278: 5947-5951. cited by applicant Malik et al., 2000, Trends in Biochemical Sciences, 25: 277-283. cited by applicant Manteuffel-Cymborowska, 1999, Acta Biochimica Polonica, 46: 77-89. cited by applicant Marin et al., Geriatrics, 57: 36-40, 2002. cited by applicant McGregor et al., 1993, Diseases of the Colon & Rectum, 36: 834-839. cited by applicant McKenna et al., 1999, The Journal of Steroid Biochemistry and Molecular Biology, 69: 3-12. cited by applicant McMurtry et al., 2005, The Journal of Clinical Investigation, 115(6): 1479-1491. cited by applicant Miller et al., 1999, Oncogene, 18: 7860-7872. cited by applicant Miloloza et al., 2000, Human Molecular Genetics, 9: 1721-1727. cited by applicant Min et al., 1998, Genes & Development, 12: 3156-3161. cited by applicant Molenaar et al., 1996, Cell, 86: 391-399. cited by applicant Monkley et al., 1996, Development, 122: 3343-3353. cited by applicant Moon et al., 1997, Trends in Genetics, 13: 157-162. cited by applicant Morin et al., 1996, Proceedings of the National Academy of Sciences of USA, 93, 7950-7954. cited by applicant Morin et al., 1997, Science, 275: 1787-1790. cited by applicant Moss et. al., 2001, American Journal of Respiratory and Critical Care Medicine, 163: 669-671. cited by applicant Motoyama et al., 1998, Nature Genetics, 20: 54-57. cited by applicant Muller-Spahn et al., 1999, European Archives of Psychiatry and Clinical Neuroscience, 249 Suppl. 3: 37-42. cited by applicant Munoz-Elias et al., 2003, Stem Cells, 21: 437-448. cited by applicant Nicolaou et al., 1994, Angewandte Chemie International Edition in English, 33: 183-186. cited by applicant Nilsson et al., 2002, Cancer Chemotherapy and Pharmacology, 49: 93-100. cited by applicant Nusse et al., 1992, Cell, 69: 1073-1087. cited by applicant Ogawa et al., 2000, Gene, 245: 21-29. cited by applicant Okanami et al., 1996, Genes to Cells, 1 :87-99. cited by applicant Orford et al., 1999, The Journal of Cell Biology, 146: 855-867. cited by applicant O'Shea et al., 1991, Neuron, 7: 231-7. cited by applicant Pachernik et al., 2002, Reproduction Nutrition Development, 42: 317-326. cited by applicant Parr et al., 1994, Current Opinion in Genetics & Development, 4: 523-528. cited by applicant Parr et al., 2001, Developmental Biology, 237: 324-332. cited by applicant Peifer et al., 2000, Science, 287: 1606-1609. cited by applicant Pellitteri et al., 2001, European Journal of Histochemistry, 45: 367-376. cited by applicant Pepicelli et al., 1998, Current Biology, 8: 1083-1086. cited by applicant Piergentili et al., “Solution-phase synthesis of ICG-001, a β-turn peptidomimetic molecule inhibitor of β-catenin-Tcf-mediated transcription,” Tetrahedron, 2007, pp. 12912-12916, vol. 63. cited by applicant Polakis, 2000, Genes & Development, 14: 1837-1851. cited by applicant Polakis et al., 2000, Colon Cancer Prevention: Dietary Modulation of Cellular and Molecular Mechanisms (Advances in Experimental Medicine and Biology), 470: 23-32. cited by applicant Randolph et al., 1995, Journal of the American Chemical Society, 117: 5712-19. cited by applicant Robyr et al., 2000, Molecular Endocrinology, 14: 329-347. cited by applicant Rocchi et al., 2003, Brain Research Bulletin, 61: 1-24. cited by applicant Rodova et al., 2002, The Journal of Biological Chemistry, 277: 29577-29583. cited by applicant Roose et al., 1999, Science, 285: 1923-1926. cited by applicant Rowan et al., 2003, Philosophical Transactions of the Royal Society B: Biological Sciences, 358: 821-828. cited by applicant Rubinfeld et al., 1996, Science, 272: 1023-1026. cited by applicant Rubinfeld et al., 1997, Science, 275: 1790-1792. cited by applicant Rydel et al., 1988, Proceedings of the National Academy of Sciences of USA, 85: 1257-1261. cited by applicant Sakanaka et al., 1998, Proceedings of the National Academy of Sciences of USA, 95: 3020-3023. cited by applicant Sakanaka et al., 1999, The Journal of Biological Chemistry, 274: 14090-14093. cited by applicant Sant'Angelo et al., 2003, Neurochemical Research, 28: 1009-1015. cited by applicant Sata, 2003, Trends in Cardiovascular Medicine, 13: 249-253. cited by applicant Sata et al., 2002, Nature Medicine, 8: 403-409. cited by applicant Satoh et al., 1999, Biochemical and Biophysical Research Communications, 258: 50-53. cited by applicant Selman et al., 2000, American Journal of Physiology—Lung Cellular and Molecular Physiology, 279: L562-L574. cited by applicant Shawler et al., 1995, Journal of Immunotherapy with Emphasis on Tumor Immunology, 17: 201-8. cited by applicant Shih et al., 1996, Proceedings of the National Academy of Sciences of USA, 93: 13896-13901. cited by applicant Shikama et al., 1997, Trends in Cell Biology, 7: 230-236. cited by applicant Shtutman et al., 1999, Proceedings of the National Academy of Sciences of USA, 96: 5522-5527. cited by applicant Shu et al., 2002, Development, 129: 4831-4842. cited by applicant Simonet et al., 1995, Proceedings of the National Academy of Sciences of USA, 92: 12461-12465. cited by applicant Simosa et al., 2005, Journal of Vascular Surgery, 41: 682-690. cited by applicant Skubitz et al., 1991, The Journal of Cell Biology, 115: 1137-1148. cited by applicant Smalley et al., 1999, Cancer and Metastasis Reviews, 18: 215-230. cited by applicant Song et al., 2000, The Journal of Biological Chemistry, 275: 23790-23797. cited by applicant Sprenger-Haussels et al., 2000, Plant Journal, 22: 1-8. cited by applicant Stavridis et al., 2003, Biochemical Society Transactions, 31: 45-49. cited by applicant Stein et al., 1990, Journal of Virology, 64: 4421-4427. cited by applicant Storey et al., 2002, Frontiers in Bioscience 7: e155-184. cited by applicant Strovel et al., 1999, Experimental Cell Research, 253: 637-648. cited by applicant Su et al., 1993, Science, 262: 1734-1737. cited by applicant Takahashi et al., 2000, International Journal of Cancer, 85: 243-247. cited by applicant Takemaru et al., 2000, The Journal of Cell Biology, 149: 249-254. cited by applicant Tapia et al., 2006, Proceedings of the National Academy of Sciences of USA, 103: 15079-15084. cited by applicant Tebar et al., 2001, Mechanisms of Development, 109: 437-440. cited by applicant Tetsu et al., 1999, Nature, 398: 422-426. cited by applicant Tsukamoto et al., 1988, Cell, 55: 619-625. cited by applicant Tsunoda et al., 1999, Anticancer Research, 19: 1149-52. cited by applicant Uhal et al., 1995, American Journal of Physiology—Lung Cellular and Molecular Physiology, 269: L819-L828. cited by applicant Uhal et al., 1998, American Journal of Physiology—Lung Cellular and Molecular Physiology, 275: L1192-L1199. cited by applicant Ulmasov et al., 1999, Proceedings of the National Academy of Sciences of USA, 96: 5844-5849. cited by applicant U.S. Appl. No. 61/105,088, filed Oct. 14, 2008. cited by applicant Vanhems et al., 1990, European Journal of Neuroscience, 2: 776-782. cited by applicant Verstijnen et al., 1988, Anticancer Research, 8: 1193-1200. cited by applicant Vetter et al., 1995, Current Biology, 5: 168-178. cited by applicant Wan et al., 2003, Chinese Medical Journal, 116: 428-431. cited by applicant Wang et al., 2005, Arteriosclerosis, Thrombosis, and Vascular Biology, 25: 2081-2087. cited by applicant Warburton et al., 2000, Mechanisms of Development, 92: 55-81. cited by applicant Weaver et al., 1999, Development, 126: 4005-4015. cited by applicant Weeraratna et al., 2002, Cancer Cell, 1: 279-288. cited by applicant Weidenfeld et al., 2002, The Journal of Biological Chemistry, 277: 21061-21070. cited by applicant Weiner, 1997, Harvard Review of Psychiatry, 4: 306-316. cited by applicant Willed et al., 1998, Current Opinion in Genetics & Development, 8: 95-102. cited by applicant Xia et al., 2001, Proceedings of the National Academy of Sciences of USA, 98: 10863-10868. cited by applicant Yamaguchi et al., 1999, Development, 126: 1211-1223. cited by applicant Yost et al., 1996, Genes & Development, 10: 1443-1454. cited by applicant Zaloom et al., 1981, The Journal of Organic Chemistry, 46: 5173-76. cited by applicant Zhang et al., 2001, Cancer Research, 61: 8664-8667. cited by applicant Zhou et al., 1997, Developmental Dynamics, 210: 305-314. cited by applicant |
| Assistant Examiner: | Kenyon, John S |
| Primary Examiner: | Kosar, Andrew D |
| Attorney, Agent or Firm: | Davis Wright Tremaine, LLP |
| Accession Number: | edspgr.09040531 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|